PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 207/16, A61K 31/401, A61P 3/10 — A1

(11) International Publication Number: WO 00/34241

(43) International Publication Date: 15 June 2000 (15.06.00)

(21) International Application Number: PCT/EP99/09708

(22) International Filing Date: 9 December 1999 (09.12.99)

(30) Priority Data:
09/209,068 10 December 1998 (10.12.98) US

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1230 Vienna (AT).


(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: VILLHAUER, Edwin, Bernard [US/US]; 20 Dorothy Drive, Morristown, NJ 07960 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH–4002 Basel (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: N–SUBSTITUTED 2–CYANOPYRROLIDINES



(I)

(57) Abstract

The present invention relates to a compound of formula (I), wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula (I) inhibit DPP–IV (dipeptidyl–peptidase–IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP–IV and in the treatment of conditions mediated by DPP–IV, such as non–insulin–dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.